Krish Patel, MD

Krish Patel, MD, an oncologist at the Swedish Cancer Institute, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma (MCL).

Moving forward, Patel thinks it will be interesting to see how CAR T-cell therapy evolves in this space. This is an exciting area of research for MCL, as well as the other lymphoid malignancies where these agents are also being investigated. However, it is too early to know the ultimate impact of this research.

Videos

Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.

Expert Highlights Areas of Research in MCL

Kris Patel, MD, an oncologist at the Swedish Cancer Institute, discusses the real-world data for ibrutinib (Imbruvica) in patients with relapsed/refractory mantle cell lymphoma (MCL) as compared to clinical trials.

Patel says there were 2 major takeaways from these data. First, the overall response and clinical benefit was about the same between the real-world population and the clinical trial results. This shows that the response in the real-world can mirror those in a clinical trial.

Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.

Krish Patel, MD | Authors

Articles

Expert Highlights Areas of Research in MCL

Real-World Data for Ibrutinib in Relapsed/Refractory MCL